Replies to post #167 on Endocyte Inc fka ECYT

[drchik23]

Thanks for the post. Couple of things I just wanted to add. All minor points, perhaps:

ECYT was told in August that their drug would be under review for about 57 days to achieve this status (along with drugs from other companies.) It took 6 months, wow.

http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/10/WC500116272.pdf


If they do get approved in EU, orphan drug status usually allows for 10 years of marketing exclusivity.

http://en.wikipedia.org/wiki/Orphan_drug_status

And finally, the feb 9th news didn't seem to impact the stock. It closed up 2 cents. The 14th and 15th of Feb is when we finally saw saw real buying on heavy volume. Not sure if it was a delayed response, value investors, or what?

Let's see what next two days tell us. March will be important. We have earnings and possible news end of month. But first........to tomorrow............

http://investor.endocyte.com/events.cfm